PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

BACKGROUND: Despite the availability of effective drug therapies that reduce low‐density lipoprotein (LDL)‐cholesterol (LDL‐C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL‐C reduction may be warranted, especially for people who are un...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cochrane Database Syst Rev
Main Authors: Schmidt, Amand F, Carter, John-Paul L, Pearce, Lucy S, Wilkins, John T, Overington, John P, Hingorani, Aroon D, Casas, JP
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Ltd 2020
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8094613/
https://ncbi.nlm.nih.gov/pubmed/33078867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD011748.pub3
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki